ziprasidone + Placebo

Phase 2Completed
0 watching 0 views this week Active
51
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Borderline Personality Disorder

Conditions

Borderline Personality Disorder

Trial Timeline

Mar 1, 2004 → Apr 1, 2006

About ziprasidone + Placebo

ziprasidone + Placebo is a phase 2 stage product being developed by Pfizer for Borderline Personality Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00635921. Target conditions include Borderline Personality Disorder.

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
5
Community
5

Clinical Trials (5)

NCT IDPhaseStatus
NCT03768726Phase 3Terminated
NCT01172652ApprovedCompleted
NCT00483548Phase 3Completed
NCT00374543ApprovedTerminated
NCT00635921Phase 2Completed